Molly Henderson

Molly Henderson is a declared insider at 3 companies (finance chief); the most frequent names are Phathom Pharmaceuticals, Inc., UroGen Pharma Ltd. and Advaxis, Inc. Over a trading history stretching from 12 June 2018 to 7 April 2025, the count stands at 33 filings.

In open-market terms, that means 2 purchases worth €33k on one side and 16 sales worth €447k on the other. The totals exclude 1 filing filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 13 share grants and 2 option exercises. Since January 2025: no purchases and 2 sales on the market.

On 8 April 2025 came the latest disclosure, an open-market sale for €15k in Phathom Pharmaceuticals, Inc. The clock since the last published purchase (16 May 2022) now reads 1,622 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.